Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made it this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. Our choice today is the refreshing cinnamon hazelnut. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch. …
Resistance to medicines for combating superbugs has considerably worsened during the pandemic, with deaths and infections from several serious pathogens increasing at least 15% during the first year of the crisis, STAT writes, citing a new report by the Centers for Disease Control and Prevention. The increased rates for some infections, however, were much larger. For instance, there was a 78% jump among those infected with Acinetobacter, a gram-negative bacteria. Moreover, after years of steady declines in health care-associated infections, U.S. hospitals saw significantly higher rates for four out of six types of infections in 2020.
Teva Pharmaceutical and AbbVie’s Allergan unit reached a $58 million settlement with the city of San Francisco just before completion of a trial over claims that they fueled an opioid epidemic in the city, Reuters reports. Under the deal announced by City Attorney David Chiu, Teva will pay $25 million in cash and contribute a $20 million supply of the overdose-reversal drug Narcan. AbbVie will pay $13 million. The settlement was reached before closing arguments in a trial that kicked off on April 25. San Francisco proceeded with closing arguments on Tuesday against retail pharmacy chain Walgreens, the last remaining defendant in the case.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
